Drug intelligence / Profile preview

GTE-001

Development stage: Unknown
Lead developer: Grit Biotechnology
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Injection, Intravenous

Overview

GTE-001 is an autologous tumor-infiltrating lymphocyte (TIL) therapy under development by Grit Biotechnology for the treatment of advanced adenocarcinoma, including lung adenocarcinoma. The product consists of T cells isolated from a patient's own tumor, expanded ex vivo, and then re-infused to target and attack cancer cells. It is administered via injection and represents a form of cell therapy designed to harness the patient’s immune system against malignancy. As of now, it is in phase 1 clinical trials in China for adenocarcinoma[1][2][3].

Other names: Autologous Tumor-Infiltrating LymphocyteGTE-001 InjectionGTE001 InjectionGTE 001 Injection

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on GTE-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTE-001.

Explore the full profile